Xilio Therapeutics' Q3 collaboration revenue rises

Xilio Therapeutics

13/11/2025 12:42

Overview

Xilio Q3 collaboration revenue rises to $19.1 mln from $2.3 mln year-over-year

Net loss for Q3 widens to $16.3 mln from $14.0 mln year-over-year

Company anticipates cash runway into Q1 2027

Outlook

Xilio plans to submit IND for XTX501 in mid-2026

Company anticipates cash runway into Q1 2027

Xilio seeks partner for vilastobart combination therapy

Result Drivers

R&D expenses were $14.3 million for the quarter ended September 30, 2025, compared to $10.8 million for the quarter ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 Net Income
-$16.29 mln
Q3 Income from Operations
-$1.93 mln
Q3 Operating Expenses
$21 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy."

Wall Street's median 12-month price target for Xilio Therapeutics Inc is $2.00, about 61.3% above its November 12 closing price of $0.77

Press Release: ID:nGNX93lVSl

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)